Now that hepatitis C virus has many therapeutic options, biopharma companies have turned their attention to finding a potential cure – or at least a functional cure – for hepatitis B virus (HBV), targeting not only the reservoir virus but also finding ways to boost immunity, as they continually seek research funding.